Abiopharma

(99% Neutral) I-Mab (IMAB) Files Form 6-K

(10% Negative) Keros Therapeutics, Inc. (KROS) Announces Delay in observed Development Timeline Due to Pandemic-Related Challenges, Manufacturing Considerations, Safety Review

(99% Neutral) Inovio Pharmaceuticals, Inc. (INO) Announces New Board Appointment

(99% Neutral) HARVARD BIOSCIENCE, INC. (HBIO) Announces Executive Changes

(10% Negative) Aquestive Therapeutics, Inc. (AQST) Announces Delay in assist Trials for management transition WARREN Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(10% Negative) Keros Therapeutics, Inc. (KROS) Announces Delay in included Trials for Fulton index Due to Pandemic-Related Challenges, Manufacturing Considerations

(99% Neutral) Pacific Biosciences of California, Inc. (PACB) Announces New Board Appointment

(90% Positive) Sanofi (SNY) Announces Clinical Development Update (Form 6-K)

(99% Neutral) Genmab (GMAB) Announces Clinical Development Update (Form 6-K)

(99% Neutral) TALARIS THERAPEUTICS, INC. (TALS) Announces Clinical Development Update